Pharmacy Question for the Week of September 11, 2017

Pharmacy Compliance Question of the Week

Question:

For the last quarter of 2017, are there any additional drugs with pass-through status?

Answer:

Effective October 1, 2017, the Centers for Medicare & Medicaid Services (CMS) granted outpatient prospective payment system  pass-through status to the four drugs below:

C9491 Injection, avelumab, 10 mg
C9492 Injection, durvalumab, 10 mg
C9493 Injection, edaravone, 1 mg
C9494 Injection, ocrelizumab, 1 mg

 

Disclaimer: Every reasonable effort was made to ensure the accuracy of this information at the time it was published. However, due to the nature of industry changes over time we cannot guarantee its validity after the year it was published.